期刊文献+

宫颈癌盆腔淋巴结转移根治性放疗的疗效 被引量:8

Study of Radiotherapy in the Treatment of Cervical Cancer with Pelvic Lymph Node Metastases
暂未订购
导出
摘要 目的探讨宫颈癌盆腔淋巴结转移根治性放疗的疗效和不良反应。方法对48例盆腔淋巴结转移的宫颈癌患者行根治性放疗,44例同时辅助全身化疗。采用6~18 MVX射线前后对穿两野或前后对穿两野+左右侧野的四野照射,全盆腔照射DT30~40 Gy后中间铅挡加量DT10~20 Gy,使B点DT达50 Gy。盆腔转移的淋巴结局部小野补量(RT)照射,每次DT2 Gy,总DT8~10 Gy,高剂量后装治疗(HDR)采用核通后装机治疗,192Ir治疗,选取A点参考点,处方剂量为600~700 cGy,每周1次,共6次。结果随访时间为22~43个月,中位随访时间31个月,随访率100.00%。PR、CR分别达100.00%和83.33%(40/48),盆腔转移淋巴结完全有效率为85.42%(41/48)。结论盆腔转移淋巴结照射剂量达60 Gy以上,疗效好,无严重消化道不良反应发生。 Objective To evaluate the efficacy and toxicities of radiotherapy in the treatment of cervix carcinomas with pelvic lymph node metastases.Methods From May.2008 to May.2010,48 patients with histologically proved cervix cancer were selected.44 were squamous carcinoma,3 were adenocarcinoma,1was adenosquamous carcinoma.According to the FIGO system,2 cases were stage Ⅱa,12cases Ⅱb,4 cases Ⅲa,30 cases Ⅲb.44 cases combinded with chemotherapy.All of the patients began with conventional fractionated radiotherapy by 6-18MVX-ray to a total dose of DT30-40 Gy in 3 to 4 weeks,followed by center shielding to DT 10-20 Gy.which made point B to DT 50 Gy.Patients with pelvic lymph nodes metestases got boost to DT58-60 Gy.HDR was performed weekly and concurrently with the centrally shieded EBRT.5-7 sessions were applied in the process of the brachytherapy.Results All patients completed the treatment planning with a mean followed-up of 31 months.CR was 83.33%(40/48)and PR was 100.00%(48/48),29 patients developed gradeⅡto Ⅲ gastrointestinal reaction.3 patients got rectal bleeding,No patients developed sigmoind and rectal ulcers.Conclusion Radiotherapy could give favorable local control for cervix carcinomas with pelvic lymph node metastases.
出处 《实用癌症杂志》 2013年第1期77-79,共3页 The Practical Journal of Cancer
关键词 宫颈癌 放射治疗 盆腔转移淋巴结 照射剂量 Cervical cancer Radiotherapy Pelvic lymph node Radiation dose
  • 相关文献

参考文献9

  • 1Yang WT,Lam WW,Yu MY. Comparison of dynamic helical CT And dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma[J].American Journal of Roentgenology,2000.759.
  • 2Choi HJ,Kim SH,Seo SS. MRI for pretreatment lymph node staging in uterine cervical cancer[J].American Journal of Roentgenology,2006.538.
  • 3Bonin SR,Lanciano RM,Corn BW. Bony landmarks are not anadequate substitute for lymphangiography in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy[J].International Journal of Radiation Oncology,Biology,Physics,1996,(01):167.
  • 4Nag S,Erickson B,Thomadsen B. The American Brac-hytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J].International Journal of Radiation Oncology,Biology,Physics,2000,(01):201.
  • 5Eifel PJ,Berek JS,Markman MA. Cancer of the cervix,Vagina,and Vulva[A].Philadelphia:Lippincott Williams and Wilkins,2008.1515.
  • 6Logsdon MD,Eifel PJ. Figo ⅢB squamous cell carcinoma of the cervix:an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy[J].International Journal of Radiation Oncology,Biology,Physics,1999,(04):763.
  • 7Elizabeth AK,Barry AS,Farrokh D. Lymph node staging by positron emission tomography in cervical cancer:relationship to prognosis[J].Journal of Clinical Oncology,2010,(12):2018.
  • 8Lee LJ,Sadow CA,Russell A. Correlation of point B and lymph node dose in 3D-Planned high-dose-rate cervical cancer brachytherapy[J].International Journal of Radiation Oncology,Biology,Physics,2009,(03):803.
  • 9Havrilesky LJ,Kulasingam SL,Matchar DB. FDG-PET for management of cervical and ovarian cancer[J].Gynecologic Oncology,2005.183.

同被引文献68

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1797
  • 2Stephanie C.Han,章青,陆嘉德.大肿块ⅠB、ⅡA期及局部晚期宫颈癌的治疗[J].中国癌症杂志,2006,16(11):890-895. 被引量:7
  • 3温宏武,孙晓梅,刘喆,廖秦平.子宫颈癌盆腔淋巴结转移规律及其临床意义[J].中国实用妇科与产科杂志,2007,23(4):281-283. 被引量:11
  • 4Mutic S, Malyapa RS, Grigsby PW, et al. PET-guided IM- RT for cervical carcinoma with positive para- aortic lymph nodes-adose-escala-tion treatment planning study[ J ]. Int J Radiat Oncol Biol Phys, 2003, 55 (1) :28-35.
  • 5Nakamura K, Okumura Y, Kodama J, et aI. The predictive value of measurement of SUV max and SCC- antigen inpa- tients with pretreatment of primary squamous cell carcinoma of cervix [J]. Gynecol Oncol, 2010, 119(1):81-86.
  • 6Lim K, Small W Jr, Portelance L, et al. Consensus Guide- lines for Delineation of Clinical Target Volume for Intensity- Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer[J]. Int J Radiat Oncol Biol Plays, 2011, 79 (2) :348-355.
  • 7Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin- based chemotherapy plus radiotherapy for cervical cancer Va meta-analysis [ J ]. Clin Oncol, 2002,14 ( 3 ) :203-212.
  • 8Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intraeavitary brachytherapy combined with eis- platin chemotherapy for cervical cancer with positivepara- aortic or high common iliac lymph nodes: results of arm of RTOG 0116 [J]. Int J Radiat Oncol Biol Phys, 2007,68 (4) :1081-1087.
  • 9Kazumoto T, Kato S, Yokota H,et al. Is a Low Dose of Con- comitant Chemotherapy WithExtended- Field Radiotherapy Acceptable as an Efficient Treatment for Cervical Cancer Pa- tients With Metastases to the Para-Aortic Lymph Nodes? [J]. Int J Gyneeol Cancer, 2011, 21(8):1465-1471.
  • 10Sarkar JN, Petereit DG,Stitt JA,et al. A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma[ J]. Int J Radiat Oncol Biol Phys, 1994,30( 1 ) : 75 -82.

引证文献8

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部